Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

AGE-RELATED CHANGES IN HEMATOPOIESIS

Descripción del proyecto

La sangre nueva en la investigación abordará las enfermedades sanguíneas del envejecimiento

La sangre desempeña funciones críticas como el transporte de gases y nutrientes, la regulación de la temperatura y el pH, la coagulación sanguínea y la respuesta inmune. Las disfunciones en la hematopoyesis (proceso por el que se forman las células sanguíneas) pueden tener unos efectos perjudiciales de gran calado. A medida que envejecemos, este proceso cambia de forma natural. Sin embargo, los cambios también pueden estar relacionados con el desarrollo de patologías hematológicas, como la anemia y algunos tipos de cáncer. El proyecto financiado con fondos europeos ARCH está formando una cohorte de jóvenes científicos para estudiar el posible vínculo entre los cambios relacionados con la edad en el sistema hematopoyético y la aparición de enfermedades. Se espera que sus contribuciones repercutan en los resultados para los pacientes, la carga para el sistema sanitario y la competitividad de la Unión Europea en este campo.

Objetivo

ARCH is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific age-related hematological diseases (pediatric, adult, elderly), with the aim to develop novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and it will deploy a large panel of cutting-edge technologies, such as single cells genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 5 Partner organisations (3 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their italian nodes. ARCH will recruit 15 ESRs that will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. This broad portfolio will enable ESRs to become leading academic, clinic or industrial players in the field. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.

Coordinador

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
Aportación neta de la UEn
€ 261 499,68
Dirección
PIAZZA DELL'ATENEO NUOVO 1
20126 MILANO
Italia

Ver en el mapa

Región
Nord-Ovest Lombardia Milano
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 261 499,68

Participantes (14)

Socios (4)